What is GLOW peptide? The three-peptide blend, explained

Research-use notice: this article is for legitimate laboratory and educational research only. It does not provide guidance for human use, administration, dosing or treatment.

GLOW is the industry name for a lyophilised research blend of three peptides: GHK-Cu, BPC-157 and TB-500. It is usually supplied as 70mg in a single vial: 50mg of GHK-Cu and 10mg each of BPC-157 and TB-500, so GHK-Cu accounts for 71.4% of the label amount. GLOW is the older blend that KLOW extends by adding KPV. It is not a licensed medicine, and we know of no published study that has tested the three-peptide combination itself.

What is in a GLOW vial?

The shares follow from the label amounts: GHK-Cu is 50 of 70mg (71.4%), and BPC-157 and TB-500 are 10 of 70mg (14.3%) each. No pharmacopoeia defines GLOW, so this 5:1:1 split is a supplier convention. The label and batch report for your vial are what count.

Why is GLOW blue?

The colour comes from copper. GHK binds copper(II) through three nitrogen atoms: in glycine’s amino group, the glycine–histidine amide bond and histidine’s imidazole ring. A 2021 study in Inorganic Chemistry describes this binding site and reports a visible absorption band for the complex at 606nm, in the orange part of the spectrum. A compound that absorbs orange light looks blue. With GHK-Cu at almost three-quarters of the label amount, GLOW powder and any solution prepared from it usually have a blue tint.

That colour is a clue, not a test. GHK-Cu on its own would look the same, so the colour cannot show how much GHK-Cu is present, whether BPC-157 and TB-500 are there, or how pure anything is. Our GHK-Cu guide covers the copper chemistry in more depth.

GLOW vs KLOW: what is the difference?

KLOW is GLOW plus 10mg of KPV, the tripeptide lysine-proline-valine. The three shared components keep the same label amounts, so adding KPV changes their shares, not their quantities.

Which one fits a study design?

That depends on the research question, not the product:

• Fewer variables. If KPV is not part of the question, GLOW leaves one compound fewer to account for.
• Testing the KPV addition. A GLOW arm and a KLOW arm differ only by KPV, provided the other three components come from matched batches. That shows what adding KPV changes alongside the other three, not what KPV does alone.
• KPV alone. That needs a KPV-only arm. A 2008 study in Gastroenterology examined KPV in human intestinal cell lines and mouse colitis models; our KLOW article covers that research and the four-peptide blend.
• Fixed ratios. Neither blend lets one component be varied independently. Single-compound materials do.

Thistle supplies GLOW — 70mg Research Blend at £69.99 and KLOW — 80mg Research Blend at £84.99, each with a batch laboratory report.

GLOW vs BPC-157 + TB-500 alone

The difference is GHK-Cu. A two-peptide BPC-157 + TB-500 blend contains no copper peptide, so it is normally white rather than blue, and its report has two identities to confirm, not three. In GLOW the same two peptides make up only 28.6% of the label amount.

Combinations of BPC-157 and TB-500 are informally nicknamed the “Wolverine stack” online. That is an informal nickname, not a product name, and it defines no composition.

Unlike GLOW, the pair has been tested together. A 2026 exploratory study in Joint Diseases and Related Surgery used 32 rats in a surgical Achilles-tendon transection model, split into four groups: untreated control, BPC-157 alone, TB-500 alone, and both together. At four weeks the TB-500 group had significantly lower histopathology scores and a significantly higher load to failure than controls. Scores in the BPC-157 group were numerically lower but did not reach statistical significance, and the combination showed no additional effect over either peptide alone. It is one small animal study, without GHK-Cu. Our article on BPC-157 and TB-500 compares the two peptides in more detail.

What the published research covers

Each GLOW component has its own literature. Almost all of it comes from cell and animal models, and almost all of it was carried out on single, defined compounds rather than on a blend.

Two caveats matter. Findings for full-length thymosin beta-4 do not automatically apply to a seven-amino-acid fragment, which is why the sequence on a batch report matters. And as of October 2026 we are not aware of any peer-reviewed study of GLOW itself, so statements about what “GLOW does” are extrapolations from single-compound work, mostly in animals.

The attribution problem in a three-peptide blend

If a model exposed to GLOW shows a change, the blend design alone cannot say whether GHK-Cu, BPC-157, TB-500, an interaction between them or an impurity was responsible. A component’s share of the label amount says nothing about which one matters most in a given model.

Pharmacology treats interaction as something to measure, not assume. A 2006 review in Pharmacological Reviews sets out the theory and experimental designs for assessing synergism and antagonism in drug combinations. The 2026 rat study above shows why: because it ran single-peptide arms alongside the pair, its authors could report the absence of an additive effect.

A full factorial design for three components needs eight arms, from vehicle alone to all three together. Smaller designs usually keep:

• Single-component arms for GHK-Cu, BPC-157 and TB-500, matched to the blend’s composition.
• A vehicle control handled the same way as the blend.
• A pairwise arm where an interaction is the question, such as BPC-157 with TB-500 but no GHK-Cu.
• Analytical confirmation of each component in the material actually used.

How to check a GLOW batch

A GLOW report has three identities to confirm. When you read one, check that:

• The batch number matches the vial label.
• Each component is identified, for example by mass spectrometry, rather than one result for the whole vial.
• Content is reported per component where possible, so you can see whether the 50/10/10mg split holds.
• The TB-500 sequence is clear, since the name alone does not define it.
• The method, date and report reference are stated. An HPLC area percentage describes a separation, not identity or sterility.

The GLOW product page shows the batch laboratory report for the current batch, at the time of writing GLO70-0110, and you can look up any batch on our batch report lookup. For the general method, see How to read a peptide COA and HPLC vs mass spectrometry: two different questions.

Is GLOW legal in the UK?

GLOW is not a licensed medicine in the UK, and we have found no UK marketing authorisation for any of its three components. It is supplied as a research material for laboratory use.

Presentation matters. Under regulation 2 of the Human Medicines Regulations 2012, a substance presented as treating or preventing disease in people is a medicinal product. In April 2026 the MHRA said that if clinics offering peptide injections make medicinal claims for them, those products will be treated as medicines under those Regulations. The same report noted a clinic that had described BPC-157 as “aiding tissue repair and recovery from injuries”, and the MHRA confirmed that claims of this kind were impermissible. That is why research suppliers, Thistle included, describe what has been studied and make no claims about treating, preventing or improving any condition.

Sport has its own rules. BPC-157 is named on the World Anti-Doping Agency’s 2026 Prohibited List under non-approved substances (S0), and thymosin beta-4 and its derivatives, including TB-500, are prohibited as growth factors (S2.3).

This section is general information, not legal advice.

Storage and handling

GLOW is supplied as a lyophilised (freeze-dried) powder in a sealed vial. Keep it sealed, dry and protected from heat and light, and follow the vial label and batch documentation. Its three components differ in chemistry, and one is a metal complex, so record storage conditions and dates alongside any study data. Our peptide storage guide covers the general principles.

GLOW peptide FAQs

What is GLOW peptide used for?

GLOW is supplied for laboratory research into GHK-Cu, BPC-157 and TB-500 and how they behave together. It is not licensed or approved for human or veterinary use, and we cannot give advice on personal use.

Does GLOW have side effects?

There are no human safety data for the GLOW blend. For BPC-157 alone, a 2025 systematic review found no clinical safety data. GLOW is not for human use.

What does GLOW stand for?

It is not a formal acronym or a chemical name. GLOW is an industry name for this three-peptide blend, and KLOW adds a K for KPV.

Is GLOW the same from every supplier?

Not necessarily. 50/10/10mg is the common 70mg format, but totals and ratios are not standardised. Compare the label and the batch report, not just the name.

How much does GLOW cost in the UK?

Prices vary by supplier. At the time of writing, Thistle sells GLOW 70mg at £69.99. Price says nothing about content or purity, so check the batch report.

Sources

• Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. Review.
• Maquart FX, Bellon G, Chaqour B, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation. 1993;92(5):2368–2376. Rat wound-chamber model.
• Ufnalska I, Drew SC, Zhukov I, et al. Intermediate Cu(II)-Thiolate Species in the Reduction of Cu(II)GHK by Glutathione: A Handy Chelate for Biological Cu(II) Reduction. Inorganic Chemistry. 2021;60(23):18048–18057. Laboratory chemistry.
• BPC-157 in a rat Achilles-tendon model (2003). Primary study; rats and laboratory experiments.
• Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025;21(4):485–495.
• Ho ENM, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography–mass spectrometry. Journal of Chromatography A. 2012;1265:57–69.
• Malinda et al. (1999): thymosin beta-4 in wound models. Primary study; cell and animal models.
• Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery. 2026;37(3):822–837. Rat model; four groups including the combination.
• Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. Cell lines and mouse colitis models.
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews. 2006;58(3):621–681. Review.
• UK Government. The Human Medicines Regulations 2012, regulation 2. SI 2012/1916. Definition of a medicinal product.
• World Anti-Doping Agency. Prohibited List 2026. S0 non-approved substances; S2.3 growth factors.
• Aesthetics Journal. MHRA investigates clinics following peptide claims. 15 April 2026.

Published by Thistle BioLabs, a UK supplier of research materials. This article summarises external research, not studies conducted by Thistle. Educational information only; no medical advice or recommendation for personal use.